vTv Therapeutics

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Carvana

DraftKings

ImmunityBio

Luckin Coffee

Novavax

Upstart Holdings

There are some similarities between gambling and buying high-risk, high-reward stocks. In both scenarios, you could make a great deal of money or you could lose all of it.

7 High-Risk, High-Reward Stocks to Buy in June

vTv discovered small molecule RAGE inhibitor being developed by Cantex under worldwide development and commercialization agreement vTv discovered small molecule RAGE inhibitor being developed by Cantex under worldwide development and commercialization agreement

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

HIGH POINT, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments.

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

Gamida Cell Ltd

SAB Biotherapeutics

For investors willing to do their research and take calculated risks, biotech penny stocks can offer the potential for high returns. These companies have a low market capitalization and are not yet profitable, but they offer the potential for high growth as their products gain regulatory approval and market acceptance.

Promising Upsides on these Biotech Penny Stocks

GlaxoSmithKline

Vertex Pharmaceuticals

When it comes to finding good pharma stocks to buy, I try to focus on companies that are developing drugs that can help huge numbers of people. After all, high profits are the ultimate key catalyst for stocks, and it's much easier for companies to generate gigantic profits if there is a huge demand for the products they are developing.

3 Pharma Stocks That Could Benefit from Global Healthcare Trends

Adial Pharmaceuticals Inc

Akebia Therapeutics

Asensus Surgical

Borqs Technologies

Blue Star Foods Corp

Kiromic Biopharma

Myomo

Novo Integrated Sciences, Inc.

Sono Group NV

Penny stocks under $1 to watch right now. The post 10 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Hot Penny Stocks Under $1 To Watch This Week

Penny stocks under $1 to watch this week. The post 7 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Hot Penny Stocks Under $1 To Watch This Week

HIGH POINT, N.C., March 06, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of Type 1 diabetes, today reported financial results for the fourth quarter and year ended December 31, 2022, and provided an update on recent corporate developments.

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Finding the best penny stocks to buy seems easy.

Best Penny Stocks To Buy Under $1? 4 To Watch Now

WESTON, Fla. , March 6, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, and Baptist Health Miami Cancer Institute, part of Baptist Health Cancer Care, the largest cancer program in South Florida, announced today that the U.S. Food and Drug Administration (FDA) has issued a "Study May Proceed" letter for the Miami Cancer Institute's investigator initiated clinical trial to assess the safety and effectiveness of azeliragon combined with stereotactic radiosurgery in patients with brain metastases.

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Cantex is developing azeliragon as a once-a-day pill for the treatment of glioblastoma and other cancers WESTON, Fla. , Feb. 27, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) reviewed Cantex's Investigational New Drug application and issued a "Study May Proceed" letter for Cantex's Phase 2 clinical trial to assess the safety and therapeutic effect of azeliragon in patients with newly diagnosed unmethylated glioblastoma treated with standard of care radiation therapy.

Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

HIGH POINT, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Elizabeth (Betzy) Keiley as Executive Vice President and General Counsel, effective immediately.

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

WESTON, Fla. , Jan. 9, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the treatment of glioblastoma.

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

Bionano Genomics

iCAD

Madrigal Pharmaceuticals

Schrodinger 

Verona Pharma

Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves in clinical trials.

7 Drug Stocks That Will Soar in 2023

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer

vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

VTv Therapeutics (VTVT) Reports Q3 Loss, Lags Revenue Estimates

HIGH POINT, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) today reported financial results for the third quarter ended September 30, 2022, and provided an update on recent corporate developments.

vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update

Aptorum Group Ltd - Ordinary Shares - Class A

Yatra Online

Zynex Inc

In general, finding small-cap stocks to buy can be somewhat fraught. These are stocks with market capitalizations between roughly $300 million and $2 billion.

7 Hot Small-Cap Stocks to Buy in September

HIGH POINT, N.C., Aug. 15, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) today reported financial results for the second quarter ended June 30, 2022, and provided an update on recent corporate developments.

vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced that Paul Sekhri will lead the company as President and Chief Executive Officer, effective August 1, 2022. Rich Nelson, who has been serving as Interim Chief Executive Officer since March 2, 2022, will continue to support the company as Executive Vice President, Corporate Development and as a member of the Board of Directors. Mr. Sekhri will also join vTv's Board of Directors.

vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer

HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (“CinPax”), a subsidiary of CinRx Pharma, LLC (“CinRx”). Under the terms of the agreements, CinPax acquired 4,154,549 shares of Class A Common Stock of vTv at an issue price of approximately $2.41 per share, with $6 million paid in cash at closing, and the remaining amount of $4 million payable on November 22, 2022. The agreements also provide for the issuance of 1.2 million warrants to CinRx to acquire additional shares of Class A Common Stock that become exercisable upon agreed vesting triggers (including FDA approval of TTP399 (“FDA Approval”)). In addition to the investment, the agreements set forth the terms under which vTv will leverage the CinRx team's industry experience to collaborate on the oversight of the clinical trials for pharmaceutical products that contain TTP399.

vTv Therapeutics Announces Investment by CinRx Pharma

Results confirmed TTP399 improves glycemia without increasing hypoglycemia and suggest a protective effect of TTP399 against DKA in individuals with T1D Results confirmed TTP399 improves glycemia without increasing hypoglycemia and suggest a protective effect of TTP399 against DKA in individuals with T1D

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

Energy Focus

Tonix Pharmaceuticals Hld

Check these penny stocks out for your watchlist right now The post Hot Penny Stocks to Watch That Are Climbing Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Watch That Are Climbing Right Now

vTv Therapeutics (VTVT) stock is taking off on Wednesday after entering into a funding and collaboration agreement with G42 Investments. The post vTv Therapeutics (VTVT) Stock Surges 41% on Major Investment News appeared first on InvestorPlace.

vTv Therapeutics (VTVT) Stock Surges 41% on Major Investment News

News for vTv Therapeutics Stock (VTVT)